← Every company
Anavex Life Sciences Corp Patents
What Anavex Life Sciences Corp has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
AVXL on carbonthat →Filings on file
24
Granted
1
Still pending
23
Filed under
2 names
24 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| A19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure TherapyA61K 31/341, A61P 25/08, A61K 31/165, A61K 31/27, A61K 31/4015, A61K 31/445, A61K 31/55, A61K 45/06, C07D 307/14, A61K2300/00Filed as ANAVEX LIFE SCIENCES CORP.2026-03-16Christopher U. Missling | pending |
| ANAVEX2-73 FOR THE TREATMENT OF GENETIC NEURODEVELOPMENTAL DISORDERSA61K 31/341, A61P 25/28, A61P 25/00, A61K 9/0053, A61K 9/0095, A61K 47/10, A61K 47/12, A61K 47/26, A61K 47/36Filed as ANAVEX LIFE SCIENCES CORP.2026-01-29Christopher U. Missling | pending |
| RESPONDER SELECTION AND TREATMENT WITH SIGMA-1 RECEPTOR THERAPYFiled as ANAVEX LIFE SCIENCES CORP.2025-07-09CHRISTOPHER U. MISSLING | pending |
| OPTIMIZED SIGMA-1 AGONIST METHOD OF RESPONDER SELECTION AND TREATMENTA61K 31/341, C12Q 1/6883, A61P 25/28, A61K 31/13, A61K 31/135, A61K 31/15, A61K 31/27, A61K 31/4045, A61K 31/438, A61K 31/439, A61K 31/445, A61K 31/485, A61K 31/495, A61K 31/5375, A61K 31/55, C12Q 1/6886, C12Q2600/106, C12Q2600/156, C12Q2600/158Filed as ANAVEX LIFE SCIENCES CORP.2025-07-03Christopher U. MISSLING | pending |
| USE OF ANAVEX3-71 FOR MEDICAL TREATMENTSFiled as ANAVEX LIFE SCIENCES CORP.2025-06-18CHRISTOPHER U. MISSLING | pending |
| BLARCAMESINE CORRECTION OF EEG BIOMARKERS IN FRAGILE X SYNDROMEFiled as ANAVEX LIFE SCIENCES CORP.2025-04-30DR. CHRISTOPHER U. MISSLING | pending |
| A2-73 AS A THERAPEUTIC FOR INSOMNIA, ANXIETY AND AGITATIONA61P 25/28, A61K 31/341, A61K 9/0053Filed as Anavex Life Sciences Corp.2025-04-28Christopher U. Missling | pending |
| RESPONDER SELECTION AND TREATMENT WITH SIGMA-1 RECEPTOR THERAPYFiled as Anavex Life Sciences Corp.2025-04-18Dr. Christopher U. Missling | pending |
| SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPYA61K 31/341, C07D 307/14, A61K 9/0019, A61K 9/0053, A61K 31/138, A61K 31/404, A61K 45/06, A61K2300/00Filed as Anavex Life Sciences Corp.2025-03-28Christopher U. Missling | pending |
| USE OF ANAVEX3-71 FOR MEDICAL TREATMENTSFiled as Anavex Life Sciences Corp.2025-02-27Christopher U. Missling | pending |
| COMPOSITIONS AND METHODS FOR PREVENTION OF COGNITIVE DECLINE CAUSED BY DEGENERATIVE DISEASESA61K 31/438, A61P 25/28Filed as Anavex Life Sciences Corp.2025-01-28Christopher U. Missling | pending |
| THERAPY SELECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERSA61K 31/341, A61P 25/28, A61P 25/16, C12Q 1/6883, C12Q2600/158Filed as Anavex Life Sciences Corp.2025-01-28Christopher U. Missling | pending |
| ENANTIOMERS OF A2-73, ANALOGUES, AND SIGMA AGONIST ACTIVITYA61K 31/341, A61P 25/28, C07D 231/22, G01N 33/5005Filed as Anavex Life Sciences Corp.2024-12-26Gervias Neliat | pending |
| A2-73 CRYSTALLINE POLYMORPH COMPOSITIONS OF MATTER AND METHODS OF USE THEREOFA61P 25/28, C07D 307/14, A61K 9/28, A61K 9/2833, A61K 9/7023, A61K 31/341, C07B2200/13Filed as Anavex Life Sciences Corp.2024-12-17Christopher U. Missling | pending |
| METHODS OF USING SURROGATE BIOMARKERS IN SIGMA-1 RECEPTOR THERAPYFiled as ANAVEX LIFE SCIENCES CORP.2024-11-27CHRISTOPHER U. MISSLING | pending |
| TREATMENT OF CARDIAC DYSFUNCTIONA61K 31/34, A61P 9/00, A61P 9/06, A61K 31/341Filed as Anavex Life Sciences Corp.2024-11-08Christopher U. Missling | pending |
| GENE PATHWAYS OF RETT SYNDROMES AND USES THEREOFFiled as Anavex Life Sciences Corp.2024-09-23Dr. Christopher U. Missling | pending |
| TREATMENT AND PREVENTION OF CEREBRAL ATROPHYFiled as ANAVEX LIFE SCIENCES CORP.2024-09-09DR. CHRISTOPHER U. MISSLING | pending |
| METHODS FOR PREVENTION AND EARLY TREATMENT OF ALZHEIMER'S DISEASEFiled as Anavex Life Sciences Corp.2024-07-10Dr. Christopher U. Missling | pending |
| BLARCAMESINE CORRECTION OF EEG BIOMARKERS IN FRAGILE X SYNDROMEFiled as Anavex Life Sciences Corp.2024-07-09Dr. Christopher U. Missling | pending |
| USE OF ANAVEX3-71 FOR MEDICAL TREATMENTSFiled as Anavex Life Sciences Corp.2024-06-18Dr. Christopher U. Missling | pending |
| THERAPY SELECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERSA61P 25/28, C12Q 1/6883, A61K 31/341, A61K 45/06, C12Q2600/106, C12Q2600/158, G01N2800/28, G01N2800/52Filed as Anavex Life Sciences Corp.2024-05-22Christopher U. Missling | pending |
| BLARCAMESINE CORRECTION OF EEG BIOMARKERS IN FRAGILE X SYNDROMEFiled as Anavex Life Sciences Corp.2024-05-01Dr. Christopher U. Missling | pending |
| Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereofA61K 31/495, A61P 25/02Filed as Anavex Life Sciences Corp.2024-01-18Christopher U. Missling | 12533352 |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on AVXL
Company overviewEverything on AVXL in one place, with the price.SEC filingsWhat AVXL's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat AVXL's own officers and directors buy and sell.Who owns itEvery manager reporting a position in AVXL.Funds holding itWhich funds and ETFs hold AVXL, and how big a bet.LobbyingWhat AVXL spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on AVXL's account, and who they worked for.